Chapter 1. Renal Disease Therapeutics Market – Scope & Methodology
1.1    Market Segmentation
1.2    Assumptions
1.3    Research Methodology
1.4    Primary Sour
1.5    Secondary Sources
Chapter 2. Renal Disease Therapeutics Market – Executive Summary
2.1    Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2    Key Trends & Insights
2.3    COVID-19 Impact Analysis
           2.3.1    Impact during 2023 – 2030
           2.3.2    Impact on Supply – Demand
Chapter 3. Renal Disease Therapeutics Market – Competition Scenario
3.1    Market Share Analysis
3.2    Product Benchmarking
3.3    Competitive Strategy & Development Scenario
3.4    Competitive Pricing Analysis
3.5    Supplier - Distributor Analysis
Chapter 4. Renal Disease Therapeutics Market - Entry Scenario
4.1     Case Studies – Start-up/Thriving Companies
4.2     Regulatory Scenario - By Region
4.3    Customer Analysis
4.4     Porter's Five Force Model
           4.4.1     Bargaining Power of Suppliers
           4.4.2     Bargaining Powers of Customers
           4.4.3    Threat of New Entrants
           4.4.4    .Rivalry among Existing Players
           4.4.5    Threat of Substitutes
Chapter 5. Renal Disease Therapeutics Market - Landscape
5.1     Value Chain Analysis – Key Stakeholders Impact Analysis
5.2    Market Drivers
5.3    Market Restraints/Challenges
5.4    Market Opportunities
Chapter 6. Renal Disease Therapeutics Market By Treatment
6.1    Dialysis Equipment
6.2    Distal Embolic Protection Devices
6.3    Renal Denervation Devices
6.4    Wearable Artificial Kidney Device
Chapter 7. Renal Disease Therapeutics Market -  By Application
7.1    Anemia
7.2    Chronic Kidney Disease
7.3    Diabetes
7.4    End-Stage Kidney Disease
7.5    Hypertension
7.6    Kidney Failure
7.7    Kidney Stone Disease
Chapter 8. Renal Disease Therapeutics Market – By Region
8.1    North America
8.2    Europe
8.3    Asia-Pacific
8.4    Latin America
8.5    The Middle East
8.6    Africa
Chapter 9. Renal Disease Therapeutics Market - Company Profiles – (Overview, Product Portfolio, Financials, Developments)
9.1    Company 1
9.2    Company 2
9.3    Company 3
9.4    Company 4
9.5    Company 5
9.6    Company 6
9.7    Company 7
9.8    Company 8
9.9    Company 9
9.10    Company 10